Mercado's market performance in China

Medicines.com, Feb9, 2016 , the msSAEast (MSD) nerve industry pipeline made significant progress in its Phase I clinical trial of the Alzheimer's drug, the BACE1 inhibitor verubecestatIt also bodes well for The Ological East's pharmaceutical leadershipZhongkang CMH data show that in 2015, The sales scale of MersaDong in the five terminals was 12.65 billion yuan, with 0.92% of the domestic drug market in the 19th place, ranking 8th among domestic multinational pharmaceutical companiesAccording to informaPharma Intelligence's 2016 Global 100 Mandatory DrugRanking, Mercado is the fifth-largest pharmaceutical company with $38.5 billion in sales (by 2015 sales), and according to its latest results, its 2016 global revenue was $39.807 billion, a growth rate of 0.78 percentIn 2016, the market for new drugs in Mercadon made steady progress, with the hepatitis C drug Zepatier approved by the European Commission for the use of ribavirin (RBV) for genotypes 1 and 4 (GT-1, GT-4) chronic hepatitis C virus (H) CV) Treatment for adult infections, the new cancer drug Keytruda (pembrolizumab) has been approved by the U.SFood and Drug Administration (FDA) for treatment of patients with non-rectructable or metastatic melanoma after ipilimumab (ipilimumab) therapyFigure 1 Mercado's global sales2013-2016
In 2015, Mershadon was 19th in the Chinese mainland with a market share of 0.92%, according to Zhongkang CMHIn 2013-2015, MersaDong's market share was relatively stable in the Chinese market and is expected to increase in 2016 (Figure 1)Figure 2 Moshadeast 2013-2016 domestic market share changes
Zhongkang CMH data show that in 2015, Moshadon in the five terminals sales scale of 12.65 billion yuan, in the domesticpharmaceuticalmarket with 0.92% of the market share in the 19th place, in the domestic multinational pharmaceutical enterprises ranked 8thFigure 3 In 2013-2016, The analysis of MersaDong's product sales channels in ChinaZhongkang CMH data show that the proportion of Mershadeast products in the city grade showed a small downward trendWith the grass-roots first diagnosis, graded diagnosis and treatment and other grass-roots medical reform policy continueto in-depth, prescription into the grass-rootshospitaland retaildrugstores, county hospital terminal market potential is strong, major foreign enterprises have sunk channels, is expected in 2016 Mershadon in the county grade hospital size will increaseFigure 4 The distribution of domestic market drug use in 2015In 2015, Mersadong's products in China are mainly concentrated in the fields of cardiovascular system drugs, systemic anti-infective drugs, reproductive urinary system and sex hormone drugsThe company's total annual sales in China are cardiovascular system drug chloratan potassium tablets; systemic anti-infective drug injection with amine penanissitriata, reproductive urinary system and sex hormone drug finasamine tabletsin 2015, the top 10 products in The Mersaeast terminal sales accounted for 82.87 percent of the company's annual end-of-company sales, 8 in the growth, the fastest growth is the sodium arunnial, growth rate of 46.35 percent, while the net decline in injectable acetate carpoffin is more obvious, up to 17.63 percentFigure 5 2013-2016 E chlorsatan potassium tablets (Mercadon) changes in the market share of drugs in the domestic cardiovascular system
chlorsatan potassium is a drug used to treat primaryhypertension , suitable for patients with combined drug therapy, belongs to the angiotensin II receptor antagonists According to Zhongkang CMH data, in 2015, the chlorsatan potassium tablets in Mercadon accounted for 0.63% of the cardiovascular drug market, with annual end-of-life sales of 1.6 billion yuan Figure 6 2013-2016E Injection with amine penanasibuttin sodium (Mercadong) in the domestic systemic anti-infective drug market share change
injection with amine penanasidine sodium is a very broad spectrum of antibiotics, especially suitable for a variety of pathogens and oxygen/anaerobic bacteria-induced mixed infections, as well as early treatment before the pathogen is not determined Zhongkang CMH data show that in 2015, The injection of amine penanasibutan sodium accounted for 0.92% of the systemic anti-infective drug market, the terminal annual sales of more than 2.2 billion yuan Figure 7 2013-2016E finase saline tablets (Mercadong) in the domestic reproductive urinary system and sex hormonedrug market share changes
finassemin tablets belong to 5-alpha reductase inhibitors, is most commonly used in the treatment of benign prostate hyperplasia (BPH) drugs, through hormone regulation mechanism to reduce the size of the prostate, reduce symptoms, increase uremia, and delay the progression of the disease Zhongkang CMH data show that in 2015, The non-salamine tablets in Mersaeast accounted for the second largest in the reproductive urinary system and sex hormone drug market, accounting for 2.39% of the overall market, with annual end-of-life sales of about 1.7 billion yuan